An Unintended Consequence Of Capital Efficient Companies

I recently read an analysis that brought together several important industry trends. On the one hand, there’s nothing in it that the public didn’t already “know”. On the other, the analysis pr...

Blockchain, Cryptocurrencies And ICOs: Separating The Wheat From The Chaff

...

Emerging Managers: Minefields Or Diamond Mines?

Are emerging managers risky? Many investors in venture funds treat them as if they are not only risky but toxically so. And yet, we find that many of the best performing funds of all time have been �...

The (Not So) Limited Partner

First, let’s get something straight. General Partners of venture capital funds are responsible for setting strategy, making investment decisions, running their firms, and all other decisions that co...

The Unexpected Winner Of The Distribution Derby

...

Life Science – Gene Therapies Provide New Hope for Families

I wanted to follow up my last post about breakthrough therapies with something a little less clinical and a little more personal. Last month I had the honor of attending a luncheon hosted by the Calli...

Life Science – Regulation Gives Way To Innovation

Over the decade of the 2000s it became increasingly clear that structural issues made investing in biotech companies a high-risk, low return game. The clinical trial process lasted a decade, and cost...

Cheap Startup Costs For Tech Firms And Low Valuations Made Micro-VC Irresistible

We spoke to the best and brightest in private equity on the West Coast and beyond - Here's Judith Elsea of Weathergage Capital SuperInvestor US 2016 took place at the Four Seasons in San Francisco, 1-...

Lightning In A Bottle: The Evolution Of Micro-VC

Micro-VC—now a teeming subset of the venture capital industry—didn’t even have a name when we at Weathergage made our first commitment to that genre in 2006. At the time, we could see that adva...